Source:http://linkedlifedata.com/resource/pubmed/id/10371345
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-6-23
|
pubmed:abstractText |
Cyclin-D1 over-expression represents one of several common alterations in the G1-S transition associated with malignancies. Conclusive evidences indicate that cyclin D1 is a proto-oncogene and the gene is amplified or rearranged in different tumour types. Since very little is known about aberrations in the G1-S transition in human renal-cell carcinoma (RCC), we have characterized the expression of cyclin D1 in 80 human renal-cell carcinomas and 12 normal kidney cortex tissues using Western blotting. The cyclin-D1-protein content varied considerably and 75% of the tumours expressed higher levels than normal kidney cortex, in contrast to 25% of the tumours either lacking cyclin D1 or with low protein levels. Although it is difficult to define aberrant expression of cyclin D1, the results might indicate that the proto-oncogene was activated in a sub-set of RCC. It is also possible that low expression of cyclin D1 represents an aberrant down-regulation of the protein. Immunohistochemical assessment of cyclin D1 in a sub-set of the tumours showed large variations in the fraction of cyclin-D1-positive cells, supporting the Western-blot analyses. Surprisingly, cyclin-D1 expression did not correlate with proliferation determined by Ki-67-antigen expression or S-phase analyses. In non-papillary renal-cell carcinomas, high cyclin-D1 expression was associated with a diploid DNA profile and smaller tumour size, but there was no association between cyclin-D1 expression and tumour stage or nuclear grade. In nonpapillary tumours, high cyclin-D1 expression was further significantly associated with a better prognosis according to univariate and multivariate analyses (p = 0.005 and 0.002 respectively), as compared with highly aggressive tumours with low cyclin-D1 levels.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
21
|
pubmed:volume |
84
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
268-72
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:10371345-Adult,
pubmed-meshheading:10371345-Aged,
pubmed-meshheading:10371345-Carcinoma, Renal Cell,
pubmed-meshheading:10371345-Cell Division,
pubmed-meshheading:10371345-Cyclin D1,
pubmed-meshheading:10371345-Female,
pubmed-meshheading:10371345-Humans,
pubmed-meshheading:10371345-Kidney Neoplasms,
pubmed-meshheading:10371345-Male,
pubmed-meshheading:10371345-Middle Aged,
pubmed-meshheading:10371345-Survival Rate
|
pubmed:year |
1999
|
pubmed:articleTitle |
Cyclin-D1 expression in human renal-cell carcinoma.
|
pubmed:affiliation |
Department of Pathology, Umeå University, Sweden.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|